Chemo plus targeted conditioning for hard-to-treat AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies a specific chemotherapy plan (called sequential CLAG-Ven) with a gentler “conditioning” treatment before a transplant or donor-based therapy. It may help people with refractory or quickly relapsing acute myeloid leukemia (AML) who have a suitable family or matched donor and can meet certain organ function and infection rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that has not responded to initial treatment or has come back quickly (refractory/relapsed).
- At study start, your bone marrow has more than 5% leukemia cells (blasts).
- You have a suitable donor: a matched sibling, a 9–10/10 matched unrelated donor, or a half-matched (haplo-identical) family donor.
- You do not have an active infection when you enroll.
- Your liver blood tests are not too abnormal (enzymes and bilirubin must be within set limits).
- Your kidney and heart function meet limits (creatinine not too high; heart pumping strength EF is at least 45%).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Hear when a new Refractory Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.